research Single-cell analysis of temporal immune cell dynamics in alopecia areata reveals a causal role for clonally expanded CD8+ T cells in disease
Clonally expanded CD8+ T cells cause alopecia areata.
Search
for
Sort by
Research
180-210 / 1000+ resultsresearch Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
Multitarget drugs are needed to better treat complex diseases.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
research Highlights from the Field of Pediatric Dermatology Research from the 2023 PeDRA Annual Conference
The conference highlighted new treatments and research in pediatric skin conditions, emphasizing collaboration and innovation.
research Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
research Transdermal Liposomal Delivery Systems: Advantages, Applications, Challenges, and Prospects
Liposomal delivery systems improve drug absorption through the skin, offering potential for better treatments.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
research Pathomechanisms of immune-mediated alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Alopecia in patients with COVID-19: A systematic review and meta-analysis
Some COVID-19 patients lose hair, with the most common type linked to male hormones and possibly increasing the risk of severe illness.
research British Association of Dermatologists living guideline for managing people with alopecia areata 2024
The guideline provides recommendations for managing alopecia areata effectively.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
research Effects of the Level and Composition of Concentrate Supplements before Breeding and in Early Gestation on Production of Different Hair Sheep Breeds
research Enhancing Quercetin Bioavailability Attenuates Aging Phenotypes via the Gut Microbiota–Intestinal Barrier Axis in Aged Mice
Bioavailable quercetin may help improve aging signs by positively affecting gut health.
research Inflammatory Skin Disease in Latin America: Treatment Challenges and Opportunities
Improving education, training, and access to affordable treatments is crucial for better managing inflammatory skin diseases in Latin America.
research British Association of Dermatologists living guideline for managing people with alopecia areata 2025
The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research BH07 The socioeconomic burden of alopecia areata
Alopecia areata causes significant financial strain, especially for women and those with severe symptoms.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research Guest Editor's Note
The supplement aims to improve care for children with alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.